ckd-516
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2009 (NCT01028859)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- TubulinINHIBITOR
Tubulin inhibitor
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ckd516
- ckd 516
- ckd-516
- ckd-516
- ckd-516
- n-(4-(3-(1h-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04696848 | Phase 1/Phase 2 (Phase 2) | Feb 24, 2021 | University of Ulsan |
| NCT03076957 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2016 | Chong Kun Dang Pharmaceutical, University of Ulsan |
| NCT01560325 | Phase 1 | Jun 1, 2012 | Chong Kun Dang Pharmaceutical, Seoul National University |
| NCT01028859 | Phase 1 | Dec 1, 2009 | Chong Kun Dang Pharmaceutical, Seoul National University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chong Kun Dang Pharmaceutical | For profit | 3 | 3 | 2 | 2009 |
| Seoul National University | Academic/Hospital | 2 | 0 | 1 | 2009 |
| University of Ulsan | Academic/Hospital | 2 | 1 | 1 | 2016 |
3 organizations
Page 1 / 1